Heiko Schöder

Memorial Sloan Kettering Cancer Center — United States

Medicine · Health Sciences

90h-index25.9kcitations675works4.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Medical Imaging Techniques and Applications(205), Lymphoma Diagnosis and Treatment(186), Radiomics and Machine Learning in Medical Imaging(139), Lung Cancer Treatments and Mutations(92), Radiopharmaceutical Chemistry and Applications(84)

Publications674 total

Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4
Journal of Clinical Oncology·2026
Bridging Radiotherapy Improves Systemic Inflammation before CAR T-cell Therapy (CAR-T)
Transplantation and Cellular Therapy·2026
Prognostic role of <scp>PET</scp> / <scp>CT</scp> volumetric parameters in paediatric Hodgkin lymphoma: A systematic review and expert recommendations from the International <scp>SEARCH</scp> for <scp>CAYAHL</scp> Group
British Journal of Haematology·2026Open Access
Immunotheranostics in Solid Tumors: Longitudinal Tracking of Human IL13Rα2 CAR-T Cells In Vivo
Journal of Nuclear Medicine·2025
Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials
UNC Libraries·2025Open Access
Shining the PSMA spotlight on peritoneal metastases in prostate cancer
European Journal of Nuclear Medicine and Molecular Imaging·2025
Enhancing Radiotherapy Quality Assurance in Lymphoma: A Rigorous Real-Time Central Review Process in AHOD2131
Klinische Pädiatrie·2025
AHOD2131: A Randomized Phase 3 Response-Adapted Trial Comparing Standard Therapy to Immuno-oncology for Children &amp; Adults with Newly Diagnosed Stage I and II Hodgkin Lymphoma
Klinische Pädiatrie·2025
Enhancing Radiation Therapy Quality Assurance in Lymphoma: A Rigorous Real-Time Central Review Process in AHOD2131
International Journal of Radiation Oncology*Biology*Physics·2025
Prognostic value of 18F-FDG PET/CT volumetric parameters in childhood, adolescent, and young adult Hodgkin lymphoma (CAYAHL): a systematic review from the international SEARCH group (Staging, Evaluation and Response Criteria Harmonization)
Klinische Pädiatrie·2025
Does increased PET avidity predict follicular lymphoma transformation? evidence from a large observational study
Blood·2025
Interim and end-of-treatment FDG-PET demonstrate limited ability to predict 3-year progression-free survival with nivolumab-AVD in first-line treatment of advanced stage Hodgkin lymphoma: Imaging sub-analysis of Phase 3 S1826 study
Blood·2025· 1 citedOpen Access
Pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter, Phase 2 trial
Blood·2025Open Access
Impact of holding therapy prior to apheresis on outcomes following CD19 CAR-T cell therapy in large B-cell lymphoma
Blood·2025
First-line salvage therapies in relapsed/refractory large B-cell lymphoma after second- or third-line CD19-directed CAR T-cell therapy
Blood·2025Open Access
Delta-Like Ligand 3 Expression and Functional Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms
JCO Precision Oncology·2025Open Access
TIP-17. LU-TARGET: A Phase 1 Study of Lutetium-177-PSMA-617 Adjuvant Radiotherapy for IDH wild type Gliomas Expressing PSMA following standard Treatment
Neuro-Oncology·2025Open Access
Apparent Diffusion Coefficient Magnetic Resonance Imaging as a Predictive Biomarker for Hypoxia, Treatment De-escalation, and Recurrence in Human Papillomavirus-Associated Oropharyngeal Cancer
International Journal of Radiation Oncology*Biology*Physics·2025
Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials
Blood Cancer Journal·2025· 1 citedOpen Access
Differential Clearance of [ <sup>177</sup> Lu]Lu-PSMA-617 from Metastatic Prostate Cancer Lesions and Normal Tissues creates a Window for Safe Application of DNA Repair Inhibitors
2025Open Access
page 1 of 34Next →

Frequent Co-authors

Steven M. Larson(18), John L. Humm(9), Mithat Gönen(9), Ariela Noy(9), Yusuf E. Erdi(7), Henry Yeung(7), Ken Herrmann(6), Sadek A. Nehmeh(6), Olivia Squire(6), Andrew D. Zelenetz(6), David J. Straus(6), Wolfgang P. Fendler(5), Thomas A. Hope(5), Dennis H. Kraus(5), Craig H. Moskowitz(5), Steven M. Horwitz(5), Paul A. Hamlin(5), Jatin P. Shah(5), Nancy Y. Lee(5), Matthias Eiber(4)